Sharma S, Houfani A, Foster L
J Biomed Sci. 2024; 31(1):52.
PMID: 38745221
PMC: 11092263.
DOI: 10.1186/s12929-024-01038-1.
McNamara G, Davis B, Dwyer D, John R, Isles A
Hum Mol Genet. 2016; 25(24):5407-5417.
PMID: 27798108
PMC: 5418837.
DOI: 10.1093/hmg/ddw357.
Nicot C
J Oncol. 2015; 2015:183590.
PMID: 26170835
PMC: 4478360.
DOI: 10.1155/2015/183590.
Zhao R, Yang H, Shin J, Phan L, Fang L, Che T
Cell Cycle. 2013; 12(6):935-43.
PMID: 23421998
PMC: 3637352.
DOI: 10.4161/cc.23883.
Busanello A, Battistelli C, Carbone M, Mostocotto C, Maione R
Nucleic Acids Res. 2012; 40(17):8266-75.
PMID: 22740650
PMC: 3458561.
DOI: 10.1093/nar/gks619.
Characterization, tissue expression, and imprinting analysis of the porcine CDKN1C and NAP1L4 genes.
Li S, Li J, Tian J, Dong R, Wei J, Qiu X
J Biomed Biotechnol. 2012; 2012:946527.
PMID: 22500112
PMC: 3303864.
DOI: 10.1155/2012/946527.
Fetal overgrowth in the Cdkn1c mouse model of Beckwith-Wiedemann syndrome.
Tunster S, Van de Pette M, John R
Dis Model Mech. 2011; 4(6):814-21.
PMID: 21729874
PMC: 3209650.
DOI: 10.1242/dmm.007328.
Beckwith-Wiedemann syndrome.
Weksberg R, Shuman C, Beckwith J
Eur J Hum Genet. 2009; 18(1):8-14.
PMID: 19550435
PMC: 2987155.
DOI: 10.1038/ejhg.2009.106.
Cdkn1c (p57Kip2) is the major regulator of embryonic growth within its imprinted domain on mouse distal chromosome 7.
Andrews S, Wood M, Tunster S, Barton S, Surani M, John R
BMC Dev Biol. 2007; 7:53.
PMID: 17517131
PMC: 1891291.
DOI: 10.1186/1471-213X-7-53.
DNAse I pre-treatment markedly enhances detection of nuclear cyclin-dependent kinase inhibitor p57Kip2 and BrdU double immunostaining in embryonic rat brain.
Ye W, Mairet-Coello G, DiCicco-Bloom E
Histochem Cell Biol. 2006; 127(2):195-203.
PMID: 17024454
DOI: 10.1007/s00418-006-0238-6.
Studies of variations of the cyclin-dependent kinase inhibitor 1C and the cyclin-dependent kinase 4 genes in relation to type 2 diabetes mellitus and related quantitative traits.
Nielsen E, Hansen L, Stissing T, Yanagisawa K, Borch-Johnsen K, Poulsen P
J Mol Med (Berl). 2005; 83(5):353-61.
PMID: 15821902
DOI: 10.1007/s00109-005-0647-3.
Genetic background of adrenocortical tumor development.
Kjellman M, Larsson C, Backdahl M
World J Surg. 2001; 25(7):948-56.
PMID: 11572037
DOI: 10.1007/s00268-001-0034-3.
Epigenotype-phenotype correlations in Beckwith-Wiedemann syndrome.
Engel J, Smallwood A, Harper A, Higgins M, Oshimura M, Reik W
J Med Genet. 2000; 37(12):921-6.
PMID: 11106355
PMC: 1734494.
DOI: 10.1136/jmg.37.12.921.
p57(KIP2) is not mutated in hepatoblastoma but shows increased transcriptional activity in a comparative analysis of the three imprinted genes p57(KIP2), IGF2, and H19.
Hartmann W, Waha A, Koch A, Goodyer C, Albrecht S, von Schweinitz D
Am J Pathol. 2000; 157(4):1393-403.
PMID: 11021841
PMC: 1850179.
DOI: 10.1016/S0002-9440(10)64652-4.
CDKN1C expression in Beckwith-Wiedemann syndrome patients with allele imbalance.
Algar E, Deeble G, Smith P
J Med Genet. 1999; 36(7):524-31.
PMID: 10424812
PMC: 1734409.
Analysis of germline CDKN1C (p57KIP2) mutations in familial and sporadic Beckwith-Wiedemann syndrome (BWS) provides a novel genotype-phenotype correlation.
Lam W, Hatada I, Ohishi S, Mukai T, Joyce J, Cole T
J Med Genet. 1999; 36(7):518-23.
PMID: 10424811
PMC: 1734395.
Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen.
Watanabe H, Pan Z, Schreiber-Agus N, DePinho R, Hurwitz J, Xiong Y
Proc Natl Acad Sci U S A. 1998; 95(4):1392-7.
PMID: 9465025
PMC: 19016.
DOI: 10.1073/pnas.95.4.1392.